Format

Send to

Choose Destination
Cancer Res. 2016 Nov 15;76(22):6495-6506. doi: 10.1158/0008-5472.CAN-16-1457. Epub 2016 Sep 26.

Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Kornelia_polyak@dfci.harvard.edu andriy.marusyk@moffitt.org.
2
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
3
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
4
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
5
BBS Program, Harvard Medical School, Boston, Massachusetts.
6
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
7
Children's Hospital, Boston, Boston, Massachusetts.
8
Department of Biochemistry and Molecular Genetics, University of Colorado, Aurora, Colorado.
9
Thomson Reuters Healthcare & Science, Encinitas, California.
10
Massachusetts General Hospital, Boston, Massachusetts.
11
Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts.
12
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
13
Lester and Sue Smith Breast Center and the Dan L Duncan Comprehensive Cancer Center, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
14
Broad Institute, Cambridge, Massachusetts.

Abstract

Using a three-dimensional coculture model, we identified significant subtype-specific changes in gene expression, metabolic, and therapeutic sensitivity profiles of breast cancer cells in contact with cancer-associated fibroblasts (CAF). CAF-induced gene expression signatures predicted clinical outcome and immune-related differences in the microenvironment. We found that fibroblasts strongly protect carcinoma cells from lapatinib, attributable to its reduced accumulation in carcinoma cells and an elevated apoptotic threshold. Fibroblasts from normal breast tissues and stromal cultures of brain metastases of breast cancer had similar effects as CAFs. Using synthetic lethality approaches, we identified molecular pathways whose inhibition sensitizes HER2+ breast cancer cells to lapatinib both in vitro and in vivo, including JAK2/STAT3 and hyaluronic acid. Neoadjuvant lapatinib therapy in HER2+ breast tumors lead to a significant increase of phospho-STAT3+ cancer cells and a decrease in the spatial proximity of proliferating (Ki67+) cells to CAFs impacting therapeutic responses. Our studies identify CAF-induced physiologically and clinically relevant changes in cancer cells and offer novel approaches for overcoming microenvironment-mediated therapeutic resistance. Cancer Res; 76(22); 6495-506.

PMID:
27671678
PMCID:
PMC5344673
DOI:
10.1158/0008-5472.CAN-16-1457
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center